16 results about "CHOP" patented technology

Purinostat mesylate (PM) for preventing and treating diffuse large B-cell lymphoma (DLBCL), an analogue thereof, a drug for combined use, and the use. PM exhibits excellent in-vivo and in-vitro anti-tumor therapeutic effects on DLBCL (DEL and DHL) subtypes with poor prognosis, DLBCL subtypes having TP53 deletion and mutation combined with a plurality of poor prognosis gene mutations, and DLBCL having TP53 mutation with double expressors, which are superior to that of most existing DLBCL clinical therapy plans. A doublet or triplet therapy of PM with rituximab, R-CHOP, venetoclax and R-CHP also exhibits excellent in-vivo therapeutic effects against DLBCL and a plurality of subtypes. Thus, PM and the drug for combined use have an important clinical significance for the DLBCL and a plurality of subtypes.

The invention discloses a composition for treating ABC type diffuse large B-cell lymphoma and application of the composition, and relates to the technical field of biological medicine. The composition comprises the chidamide and the hispidulin. According to the invention, a synergistic treatment system of the composition chidamide and hispidulin is constructed, and the problem of treatment of ABC type diffuse large B-cell lymphoma is accurately solved. According to the composition, through targeting double key targets of HDAC3 and PIM1, the synergistic interaction of epigenetic regulation and signal channel inhibition is realized, and the anti-tumor effect is remarkably improved. The invention successfully breaks through the bottleneck that the existing R-CHOP scheme is poor in curative effect and easy to relapse in the treatment of ABC subtype lymphoma, provides a brand new high-specificity treatment strategy for relapse or refractory ABC type diffuse large B-cell lymphoma, and has a wide clinical application prospect.

The invention belongs to the technical field of biological medicine, and particularly relates to an HID-1121 and CHOP combined pharmaceutical composition and application thereof. Compared with the prior art, the invention has the following advantages: the HID-1121 and CHOP combined pharmaceutical composition provided by the invention realizes a better treatment effect through the synergistic effect of the medicines.

The present invention provides a composition for preventing or treating noise-induced hearing loss, the composition containing a CHOP protein inhibitor as an active ingredient. The present invention can achieve a fundamental treatment for permanent hearing loss, for which there is no realistic therapeutic agent, by reversibly restoring a permanent threshold shift (PTS) caused by noise. Furthermore, the present invention provides a screening method capable of rapidly searching for efficient therapeutic candidates for noise-induced hearing loss with high reliability by using the CHOP protein as a screening target. In addition, the present invention provides a composition for diagnosing noise-induced hearing loss, the composition containing an agent for measuring the expression level of the CHOP protein or a nucleic acid encoding same, and a method for diagnosing noise-induced hearing loss using the composition. The present invention predicts, with high reliability, whether a threshold shift caused by noise exposure is temporary or permanent, and thus can be useful for quickly identifying subjects in need of treatment and establishing treatment strategies early.

The invention discloses an effective tool for regulating chicken sex differentiation based on an endoplasmic reticulum stress pathway and a screening and verification method thereof, the effective tool comprises a GRP78 overexpression vector and a CHOP overexpression vector, the GRP78 overexpression vector plays a role in chicken male differentiation, and the CHOP overexpression vector plays a role in chicken female differentiation. The key genes (CHOP and GRP78) of an IRE1a and CHOP pathway and a PERK-GRP78 pathway are regulated and controlled, the action mechanism of the key genes on gonad sex determining genes (such as DMRT1 and FOXL2) is discussed, and a new technical scheme is provided for poultry sex control and sex differentiation abnormity research.

The invention discloses application of brazilin in preparation of a medicine for inducing endoplasmic reticulum stress of bladder cancer cells. Experiments provided by the invention prove that brazilin can inhibit the progress of bladder cancer in vitro and in vivo, and reduce the Khib level of protein enriched in a protein folding pathway, so that endoplasmic reticulum stress is triggered, a PERK-eIF2alpha-ATF4-CHOP axis is activated, and CHOP-mediated cell apoptosis is driven. According to the application disclosed by the invention, the anti-tumor effect of the brazilin is researched by associating with Khib proteome remodeling and endoplasmic reticulum stress-induced apoptosis for the first time, and the research shows that the brazilin can be used for preparing medicines for treating bladder cancer or assisting in postoperative treatment.

A method for treating peripheral T cell lymphoma. Specifically, the present invention relates to use of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof in combination with the CHOP combination or CHOEP combination in the preparation of a drug for treating mature lymphocytic tumors.

The invention belongs to the technical field of biomedicine, and discloses application of a CHOP gene in preparation of a medicine for treating Alzheimer's disease. According to the application disclosed by the invention, the fact that the beta amyloid deposition of AD can be effectively relieved by knocking out or knocking down the CHOP gene is determined for the first time, neuroinflammation in the brain can be reduced, and the spatial learning and memory ability disorder of AD transgenic mice can be effectively improved. A new target spot is provided for AD treatment, clinical transformation value is achieved, and a preparation with the CHOP gene knocked out or knocked down can be used for preparing the medicine for treating the Alzheimer's disease.

The present invention provides: a pharmaceutical composition characterized in that a specific antibody-drug conjugate and another drug are administered in combination; and / or a method of treatment, characterized in that a specific antibody-drug conjugate and another drug are administered to an individual in combination. A pharmaceutical composition in which an anti-CD37 antibody-drug conjugate and another drug (one or more drugs selected from the group consisting of a molecular targeting drug, a drug associated with R-CHOP therapy, a drug associated with R-CHOP therapy, an alkylating agent and an immune tuning drug) are administered in combination, the anti-CD37 antibody-drug conjugate is an anti-CD37 antibody-drug conjugate in which a drug-linker represented by the following formula (in the formula, A represents a binding position to the anti-CD37 antibody) is bound to the anti-CD37 antibody through a thioether bond; and / or a method of treatment characterized by administering the anti-CD37 antibody-drug conjugate and the another drug in combination to an individual.

Novel gene editing based approaches for treating genetic diseases are disclosed. In one approach, an agent for treating a genetic disease such as Duchenne muscular dystrophy (DMD) is used to achieve reframing of a target gene in an approach referred to as ReMax ("Reframing to the Maximum"). In a second approach, an agent for treating a genetic disease such as a disease caused by a dominant gain-of-function or dominant-negative mutation(s) (e.g. certain forms of autosomal dominant retinitis pigmentosa (adRP)) is used in a strategy referred to as "Prime Chop or Change" (PCOC) to achieve the insertion of specific (correct) gene edits or inactivation of mutant alleles by the generation of inactivating mutations.

Inhibitors of C / EBP homologous protein (CHOP) are provided. The inhibitors find use in the modulation of endoplasmic reticulum (ER) stress, and the treatment of conditions involving ER stress, including neuronal conditions.

The application discloses application of self-antibodies and detection reagents thereof in preparation of a kit for evaluating drug treatment prognosis of diffuse large B-cell lymphoma, wherein the antibodies include at least one of anti-N4BP1, anti-CREB1, anti-UBAP2 or anti-DEAF1. The application can improve the curative effect prediction performance of an R-CHOP treatment scheme, so that a treatment scheme of a patient can be selected in a targeted manner.

This disclosure concerns methods for predicting treatment outcome to a cancer therapy (in particular combination therapy with CHOP or R-CHOP) by detecting the level of macrophage immunometabolism regulator (MACIR) expression in a subject, wherein an increased MACIR expression indicates likely non-responsiveness to the cancer therapy. Also provided are methods of treating refractory cancer using MACIR inhibitors.

The invention belongs to the technical field of biological medicine, and particularly relates to application of salvianolic acid A in preparation of anti-vascular aging products. The invention provides application of salvianolic acid A in preparation of products for promoting endoplasmic reticulum stress and / or resisting vascular aging. The research finds that the salvianolic acid A can effectively reduce the load of vascular senescence cells caused by high fat diet, reduce the expression of vascular senescence markers p16 and p21 and delay vascular senescence. Moreover, the danshinolic acid A can activate an endoplasmic reticulum stress PERK / eIF2alpha / CHOP signal channel, so that the apoptosis of stress senescence vascular smooth muscle cells is remarkably induced, and the number of senescence vascular smooth muscle cells after PERK is knocked out cannot be reduced.